27 Drug Discovery, Pharmaceuticals & Cannabis Testing


Stainless steel cutting mill for cannabis and hemp size reduction


Leading laboratory equipment provider, Retsch, announces the availability of its Heavy-Duty Cutting Mill SM 300 in a corrosion-resistant 316L stainless steel version. Specifically designed for applications in the pharmaceutical and food industries, all parts in contact with the sample material, including the hopper, housing, and rotor, are constructed from 316L stainless steel.


This upgraded SM 300 model also offers a 30-litre receptacle of the same material, catering to the grinding needs of large sample batches. With variable speed control ranging from 100 to 3000 rpm and a diverse array of accessories, the SM 300 is optimised for cutting substantial volumes of cannabis plant material. It can efficiently process up to 40 kg/h of flower buds without causing warming effects or ingredient loss. The mill achieves grind sizes between 1 and 20 mm, depending on the material. The resulting pulverised sample is ideal for extraction via ethanol or supercritical CO2.


For enhanced versatility, the unit can be equipped with an optional cyclone and a large 30-litre receptacle, both made of stainless steel 316L, to collect significant sample volumes. The design incorporates a fold-back hopper and smooth surfaces, ensuring swift and easy cleaning procedures.


Retsch provides a comprehensive range of mills and grinders tailored for sample preparation in cannabis and related product applications. More information online: ilmt.co/PL/6K0X


61771pr@reply-direct.com


Cutting-edge genomic array advances global pharmacogenomic research


Thermo Fisher Scientific responds to the demand for a more inclusive representation of the human genome with the introduction of its latest and most diverse genomic array, the AxiomTM PangenomiX Array*. Built upon the first draft of the pangenome, which incorporated full genetic blueprints from 47 individuals worldwide, this high-throughput microarray offers unparalleled coverage for population-scale disease investigations and pharmacogenomic research.


The prevailing large-scale genomic datasets primarily rely on European and Caucasian cohorts, limiting the understanding of genetic variations in other populations, including African, Asian, and mixed populations. The PangenomiX Array aims to address this gap by providing comprehensive genomic insights across diverse ethnicities, supporting proactive healthcare models emphasising the role of genetics in disease risk and drug response.


Distinguishing itself as the only research solution combining four assays in a single test - SNP genotyping, whole genome copy number variant detection, fixed copy number discovery, blood, and HLA typing - the PangenomiX Array facilitates advancements in disease risk and detection, population-scale research programs, ancestry testing, wellness assessments, drug efficacy trials, and drug development endeavours.


The array incorporates clinically relevant pharmacogenomic markers and pathogenic variants, offering researchers improved whole-genome imputation and a high degree of diversity for testing across various ethnic backgrounds. Already utilised in the analysis of nearly half a million ethnically diverse samples at a prominent US biobank, the PangenomiX Array contributes to inclusive research studies focused on preventing, diagnosing, and treating diseases.


Kim Caple, President of Genetic Sciences at Thermo Fisher Scientific, commented: “The PangenomiX Array marks a significant stride in diversifying genomic datasets, propelling population-scale disease testing to unprecedented levels. This development holds long-term implications for our understanding of human disease, drug development, pharmacogenomics, and ancestry. With its extensive coverage, cost-effectiveness, accuracy, and reproducibility, the array builds on our three decades of dedicated microarray research, aiming to empower research that enhances people’s longevity and well-being.”


More information online: ilmt.co/PL/A6k1 61777pr@reply-direct.com New York cannabis pesticides kit simplifi es testing


Introducing Restek’s New York Cannabis Pesticides Kit, a comprehensive solution for cannabis testing labs that includes 70 essential compounds, eliminating the need for in-house standard preparation.


With eight carefully designed ampuls, you can create a high-concentration working standard, providing greater analytical flexibility when constructing calibration curves and spiking sample matrices.


The kit is specifically formulated for the New York cannabis pesticide residue list, ensuring optimal stability and usability to guarantee the accuracy of your calibration standards. Restek offers two independently produced lots from its ISO-accredited labs to meet your stringent quality control requirements.


For your cannabis analysis needs, choose Restek, where you can find a wide range of consumables, expertly optimised chromatographic conditions, and access to troubleshooting assistance. More information online: ilmt.co/PL/WeVn


61427pr@reply-direct.com Advancing pharmaceutical quality with ATNC control


In the pharmaceutical world, the control of Apparent Total Nitrosamine Content (ATNC) is crucial. The consequences of not managing these compounds extend beyond costs, involving damage to reputation and potential health risks, including the spectre of cancer in consumers.


Effectively tackling this challenge involves a proactive approach, emphasising ATNC control at its source. Swift and effective methods for confirming samples are free of nitrosamine content down to low ppb levels, have proven elusive with existing technology and methods.


Ellutia’s Automated Total Nitrosamine Analyser (ATNA) is a beacon for pharmaceutical manufacturers navigating the complex landscape of ATNC control. The ATNA, primarily acknowledged for its prowess in nitrosamine screening, extends its capabilities to encompass rapid screening for ATNC levels down to low ppb. This system accommodates a range of sample types with minimal preparation, streamlining the analysis process.


Operational simplicity meets efficiency in the ATNA’s functionality. Samples undergo a seamless process - placed in vials with a reagent mixture, subjected to a chemical reaction by the Robotic Autosampler, and then injected into the Ellutia TEA Detector. This detector, highly sensitive and selective, detects at low ppb levels, enabling the analysis of up to 10 samples per hour.


The absence of compound separation yields a single result for total ATNC content, providing a definitive understanding for further investigation. The ATNA ensures a targeted approach, allowing pharmaceutical manufacturers to focus resources where they genuinely matter, steering clear of unnecessary investment in blank samples.


If you’re dedicated to improving pharmaceutical quality with accurate ATNC control, the ATNA provides a valuable advantage. Discover its capabilities. More information online: ilmt.co/PL/BXQe and ilmt.co/PL/KY0b


61779pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40